Alphabet Joined the Dow and Became a Top Holding in Berkshire Hathaway's Portfolio. But This Stock Could Be an Even Better Buy.

The article is primarily a bullish long-term stock-picking piece centered on Prestige Consumer Healthcare’s $1.045 billion acquisition of Breathe Right and other OTC brands. It argues the deal adds about $200 million in annual revenue and $95 million in EBITDA, expands Prestige’s brand portfolio, and supports its strategy of buying category-leading consumer health products and extending their use cases. The article also highlights Prestige’s positioning around GLP-1 side effects and its international expansion via LaCorium Health in Australia. Market impact is limited to sentiment around consumer health M&A and leverage: the acquisition lifts net leverage to roughly 4.0x EBITDA, with management targeting below 3.0x by fiscal 2028. The piece contrasts Prestige with Alphabet and other big-name stocks, ultimately framing Prestige as a quieter compounder rather than a headline-grabbing tech play.